F&S THERAPLATE LTD

Executive Summary

F&S Theraplate Ltd, a recently incorporated micro-entity in the human health sector, currently exhibits high financial risk due to negative net assets and a substantial level of long-term liabilities. While regulatory compliance is maintained and governance appears stable, the company's limited operating history and financial position warrant careful scrutiny of its debt structure and future cash flow projections. Prospective investors should conduct thorough due diligence on creditor terms and operational plans before engagement.

F&S THERAPLATE LTD - Analysis Report

Company Number: 15322715

Analysis Date: 2025-07-29 16:05 UTC

1. Risk Rating: HIGH
   The company shows significant solvency concerns with net liabilities of £29,597 as of the latest accounts. Current liabilities substantially exceed current assets, and long-term creditors further increase financial strain.

2. Key Concerns:

• Negative Net Assets and Shareholders' Funds: The company’s net liabilities suggest it is insolvent on a balance sheet basis, raising doubts about its ability to meet obligations.
• High Long-Term Creditors (£123,527): The level of non-current liabilities is large relative to the asset base, indicating potential over-reliance on debt financing or delayed repayment schedules.
• Limited Operating History and Small Scale: Incorporated only in December 2023, with micro-entity accounts and minimal share capital (£102), the company has limited operational track record to demonstrate sustainability or cash flow generation.

3. Positive Indicators:

• No Overdue Filings or Compliance Issues: Accounts and confirmation statements are up to date, showing management attention to regulatory compliance.
• Directors Actively Involved and Shareholding Concentrated Among Directors: Two directors hold significant shareholding and voting control, which may support stronger governance and commitment.
• Micro-entity Reporting and Small Employee Base: Operating as a micro-entity with only two employees may allow for lean cost structure and flexibility during early growth.

4. Due Diligence Notes:

• Investigate the nature and terms of the £123,527 long-term creditors to understand repayment obligations and any related party transactions.
• Review the company’s cash flow forecasts and business plan to assess how it intends to resolve the negative equity and achieve operational stability.
• Obtain detailed profit and loss data to evaluate revenue generation, margins, and expense management, which are not disclosed in the micro-entity accounts.
• Confirm any contingent liabilities or off-balance-sheet commitments that may impact financial health.
• Assess the background and financial capacity of directors/shareholders to support the company if additional funding is required.